[Pharmacological and clinical studies on the long acting cefaclor (S6472)].
A study in which 375 mg of S6472 was orally given to 3 healthy adult volunteers before a meal, after a light meal, and after a usual meal in the cross-over method revealed the highest levels, both in serum and urine, in cases treated before a meal. In cases administered after a light or square meal, the serum level was less, but approximately 2 micrograms/ml over 6 hours after administration. No difference was seen in the AUC. The effective rate of S6472 when given at 750 approximately 1,500 mg/day was 74.6% in 62 patients with skin or soft tissue infectious diseases. Neither subjective or objective adverse reactions were seen in any case. Clinical laboratory testing revealed 1 case each of anemia and increased BUN, for which S6472 was not responsible.
D000038:Abscess / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D002433:Cefaclor / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D002506:Cephalexin / Q000031:analogs & derivatives*; D002648:Child; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D003872:Dermatitis / Q000188:drug therapy; D004435:Eating; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D003692:Delayed-Action Preparations; D002433:Cefaclor; D002506:Cephalexin